DXCM posts strong preliminary Q4 and full-year 2025 revenue growth, beating estimates, though shares slip after the ...

DexCom, Inc. DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the ...

Continuous glucose monitoring is associated with lower all-cause mortality in older adults with diabetes and ADRD compared with self-monitoring.

While still a couple of years out, MD+DI gained some insights into Dexcom's next-generation sensor from an interview with the ...

DexCom recently reported preliminary, unaudited results showing fourth-quarter 2025 revenue of about US$1.26 billion and full-year 2025 revenue of roughly US$4.66 billion, both rising at double-digit ...

DexCom stock rose sharply Monday after the maker of glucose monitors reported better-than-expected preliminary results for ...

Dexcom (NSDQ:DXCM) today announced preliminary fourth-quarter results that included revenues that topped the consensus ...

Investing.com -- Barclays downgraded DexCom and Insulet, two large-cap diabetes device makers, to Underweight as it expects rising competition in 2026 and 2027 to weigh on valuation multiples and ...

Bernstein analyst Lee Hambright maintained a Buy rating on Dexcom today and set a price target of $86.00. Claim 70% Off TipRanks Premium. Unlock hedge fund-level data and powerful ...

Owlet, Inc. OWLT is steadily transforming from a connected baby monitor brand into a data-driven pediatric health platform, ...

Read our live updates from CES 2026 in Las Vegas to see the latest consumer gadgetry in all of its chatbot-enabled, ...

DexCom overview and recent share performance DexCom (DXCM) has drawn fresh attention as investors reassess its continuous glucose monitoring business and recent share performance, with the stock last ...